FDA grants fast track status to KYV-101 for progressive forms of MS
The U.S. Food and Drug Administration (FDA) has granted fast track status to KYV-101, Kyverna Therapeuticsā cell-based therapy candidate for people with progressive forms of multiple sclerosis (MS) that are treatment-resistant. The FDA designation is intended to accelerate the development of therapies that aim to address unmet medical…